Comparison of the efficacy of nepafenac 0.1% in quiescent Behcet's uveitis and non-uveitic healthy patients after phacoemulsification surgery

Isik M. U., Yalcindag N. F.

INTERNATIONAL OPHTHALMOLOGY, cilt.40, sa.9, ss.2345-2351, 2020 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 40 Sayı: 9
  • Basım Tarihi: 2020
  • Doi Numarası: 10.1007/s10792-020-01419-z
  • Dergi Adı: INTERNATIONAL OPHTHALMOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Agricultural & Environmental Science Database, BIOSIS, EMBASE, MEDLINE
  • Sayfa Sayıları: ss.2345-2351
  • Anahtar Kelimeler: Anterior chamber flare, Cataract, Phacoemulsification, Topical nonsteroidal anti-inflammatory drug, Uveitic eyes, NONSTEROIDAL ANTIINFLAMMATORY DRUGS, CATARACT-SURGERY, MACULAR EDEMA, INFLAMMATION, PREVENTION, 0.4-PERCENT, THERAPY
  • Ankara Üniversitesi Adresli: Evet

Özet

Purpose To compare the efficacy of nepafenac on anterior chamber flare and intraocular pressure(IOP) in healthy (group 1) and uveitic eyes (group 2) undergoing cataract surgery. Methods A retrospective, consecutive case series study. Results Among 54 the patients, 14 had a history of uveitis. The groups were similar in age and gender. There were significant changes in flare values in both groups. When the temporal changes of flare values were compared, there was no difference between the two groups. There were no significant changes in IOP values in both group. When the temporal changes of IOP values were compared, there was no difference between the groups. Conclusions Nepafenac 0.1% has been shown to be effective in suppressing inflammation after cataract surgery in uveitic eyes as well as in healthy eyes. In addition, it has been observed that it does not increase intraocular pressure in both healthy and uveitic eyes and it is safe to use with this regard.